Mesothelioma Clinical Trial Information: Immune Checkpoint Inhibitors and Targeted Therapies in Japan

• March 10, 2016
• 1 min read

Below is a summary of clinical trial information relevant to mesothelioma and rare cancer sites in Japan, provided for patient reference.

1. Phase 2 Safety Trial of PD-1 Immune Checkpoint Inhibitor for Rare Cancer Sites (Anal Cancer, Cholangiocarcinoma, Thyroid Cancer)

https://clinicaltrials.gov/ct2/show/NCT02628067

2. Gene Therapy: Clinical Trial Using Ad-SGE-REIC

A clinical trial using the gene therapy agent Ad-SGE-REIC, conducted at Okayama University.

3. Cancer Stem Cell Inhibitor BBI608 Phase 1/2 Trial

A Phase 1/2 clinical trial using BBI608, a cancer stem cell-targeting agent characterized by STAT3 inhibition. The trial is divided into two parts.

https://clinicaltrials.gov/ct2/show/study/NCT02347917

4. Phase 1 Trial Using BAY94-9343

A Phase 1 clinical trial using BAY94-9343 in patients who have not responded to standard therapy.

https://clinicaltrials.gov/ct2/show/NCT02485119

All four clinical trials include links and site information — please access the links directly for details. We receive many inquiries about rare cancer sites; unlike common sites such as lung and colorectal cancer where data is abundant, rare site data requires additional research and translation time. We apologize for the delay.

Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. This is not an encouragement to enroll in clinical trials or use any specific drugs. If the clinical trial organization has publicly posted contact information, patients may contact them directly. Please contact us if you need assistance.

Mesothelioma | Cholangiocarcinoma | Thyroid Cancer | Anal Cancer

• Immunotherapy

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4